Vitamin B3 Emerges as Affordable Solution for Fatty Liver Disease, Driven by Genetic Discovery

Metabolic-associated fatty liver disease (MASLD) impacts nearly one-third of the global population, posing significant health risks and previously offering few targeted therapies. In a major scientific breakthrough, researchers have pinpointed microRNA-93 as a crucial genetic driver behind the development of fatty liver disease. The study, published in a leading medical journal, demonstrates that vitamin B3—also known as niacin—can effectively suppress microRNA-93 activity. This suppression helps reduce fat accumulation in the liver, addressing the root cause of MASLD. Unlike many experimental drugs, vitamin B3 is widely available, affordable, and has a well-established safety profile. The findings suggest that repurposing niacin could provide an accessible and powerful new treatment for millions suffering from fatty liver disease worldwide. Experts highlight that this discovery not only paves the way for immediate clinical trials but also offers hope for a scalable intervention that could transform public health outcomes. Patients are advised to consult healthcare professionals before starting any new supplement regimen, as further research will clarify optimal dosing and long-term effects. With MASLD rates rising globally, this innovative approach marks a significant step forward in combating a disease that has long eluded effective treatment. Read the source »